XTL Biopharmaceuticals (XTLB) Stock Forecast: StockMap's 2-Week Call

XTLB stock forecast: StockMap's model calls XTL Biopharmaceuticals Strong Underperform for the two weeks after the Nov 19 close: it expects XTLB to trail the growth index. It is a call on the gap, not a price target. Right in 6 of 6 two-week windows on XTLB since Aug 21; by chance, a call on the same dates was right 59% of the time.

XTL Biopharmaceuticals last closed at $1.48, -3.90% on the session.

Against the IVW growth benchmark the position is -1.57% over the forecast window.

XTL Biopharmaceuticals' market cap is $6.45M as of November 19, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -54 (behind).

Where XTLB sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

49 daily calls for XTLB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

XTL Biopharmaceuticals is classified under Health Care / Biotechnology.

StockMap tracks XTL Biopharmaceuticals as the 369th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite XTL Biopharmaceuticals ranks 367th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

XTL Biopharmaceuticals (XTLB) — StockMap 2-week forecast & tracked accuracy